Development and validation of an UPLC-MS/MS method for the quantification of ethoxzolamide in blood, brain tissue, and bioequivalent buffers: applications to absorption, brain distribution, and pharmacokinetic studies.

The purpose of this study is to develop and validate an UPLC-MS/MS method to quantify ethoxzolamide in plasma (EZ) and apply the method to absorption, brain distribution, as well as pharmacokinetic studies. A C18 column was used with 0.1% of formic acid in acetonitrile and 0.1% of formic acid in water as the mobile phases to resolve EZ. The mass analysis was performed in a triple quadrupole mass spectrometer using multiple reaction monitoring (MRM) with positive scan mode. The results show that the linear range of EZ is 4.88-10,000.00 nM. The intra-day variance is less than 12.43% and the accuracy is between 88.88 and 108.00%. The inter-day variance is less than 12.87% and accuracy is between 89.27 and 115.89%. Protein precipitation was performed using methanol to extract EZ from plasma and brain tissues. Only 40 µL of plasma is needed for analysis due to the high sensitivity of this method, which could be completed in less than three minutes. This method was used to study the pharmacokinetics of EZ in SD rats, and the transport of EZ in Caco-2 and MDCK-MDR1 overexpressing cell culture models. Our data show that EZ is not a substrate for p-glycoprotein (P-gp) and its entry into the brain may not limited by the blood-brain barrier.

Topically active carbonic anhydrase inhibitors. 1. O-acyl derivatives of 6-hydroxybenzothiazole-2-sulfonamide.

A series of O-acyl derivatives of 6-hydroxybenzothiazole-2-sulfonamide (4, L-643,799) was prepared and the potential utility of each series member as a topically active inhibitor of ocular carbonic anhydrase was determined. In vitro studies showed these esters to be substrates for ocular esterases which liberate 4 during corneal translocation. The most interesting series member, 2-sulfamoyl-6-benzothiazolyl 2,2-dimethylpropionate (22, L-645,151), acting as a prodrug form of 4, was found to enhance delivery through the isolated albino rabbit cornea by 40-fold when compared to the parent phenol 4. Studies in rabbits revealed that 22 is a potent topically active ocular hypotensive carbonic anhydrase inhibitor.

Topical carbonic anhydrase inhibitors. III: Optimization model for corneal penetration of ethoxzolamide analogues.

An analogue series representing modification to the benzene ring of ethoxzolamide has been evaluated for solubility, pKa, partitioning, and permeability across excised rabbit corneas. These physical parameters were correlated to Hammett sigma (para) and/or Hansch pi parameter values for each compound. From these correlations, a mathematical model was developed relating corneal permeability to molecular modifications of ethoxzolamide. A three-dimensional plot of maximum attainable penetration rate versus sigma (para) and pi yielded an optimal range of pi and sigma values from which an optimally penetrating analogue could be designed.

Ocular hypotensive effects of carbonic anhydrase inhibitors in normotensive and glaucomatous Beagles.

Four carbonic anhydrase inhibitors (acetazolamide, dichlorphenamide, ethoxzolamide, and methazolamide) cause ocular hypotony in normotensive and glaucomatous Beagles. Four dosages of acetazolamide and methazolamide and three dosages of dichlorphenamide and ethoxzolamide were evaluated. The extent of ocular hypotony after these carbonic anhydrase inhibitors was usually greater in glaucomatous Beagles than it was in normotensive Beagles.

Inhibition of carbonic anhydrase in the lens does not induce myopia in cynomolgus monkeys.

Refraction was measured in eyes of cynomolgus (Macaca irus) monkeys, before and during continuous intravenous infusion of large doses of the carbonic anhydrase (CA) inhibitors acetazolamide and ethoxzolamide. No changes of refraction were seen. Therefore, inhibition of CA in lens, cornea and retina does not appear to be the cause of the transient myopia and associated symptoms, occasionally observed in patients treated with CA inhibitors.

[Clinical tests on the use of ethoxzolamide in glaucoma therapy (author's transl)]. / Klinische Untersuchungen zur Anwendung von Ethoxzolamid in der Glaukomtherapie.

Ethoxzolamide is a potent carboxyanhydrase inhibitor, and its use in chronic glaucoma and in the acute glaucoma attack is described in the present investigation. Ethoxzolamide shows itself to be extremely well tolerated. The frequency and intensity of the side-effects is low. The electrolyte balance remains also after prolonged administration compensated. The important advantage of this drug is its low dosability. Ethoxzolamide, which was already 1958 clinically evaluated (Gordon-Posner), represents a valuable medication for conservative glaucoma therapy.

Aminozolamide suspension: the role of the vehicle in a topical carbonic anhydrase inhibitor.

Aminozolamide (6-amino-2-benzothiazolesulfonamide) is a carbonic anhydrase inhibitor derived from ethoxzolamide that has been shown in gel formulation to lower IOP in rabbits, primates and humans. This study was designed to determine whether aminozolamide in suspension was also effective in lowering IOP. In separate single dose and multiple dose studies, patients with ocular hypertension were tested over 24 hours. No statistically significant drop in intraocular pressure was noted between the treated and control eye. In addition, conjunctival injection was noted in three of eleven subjects after multiple dosing. These studies suggest that retention of aminozolamide at the active site is inadequate when delivered in a suspension vehicle. In the past 10 years, efforts to develop an effective topical carbonic anhydrase inhibitor have been vigorously pursued. This has been aided by advancements in drug delivery and chemical synthesis involving molecular modification of existing carbonic anhydrase inhibitors. Various compounds have been developed that retain carbonic anhydrase inhibitory activity, penetrate the cornea and optimize the other important pharmacokinetic properties to lower intraocular pressure. One such compound, aminozolamide (6-amino-2-benzothiazolesulfonamide) is derived from ethoxzolamide. In suspension, it has been shown to lower IOP in rabbits and primates. It also has been shown to lower IOP in patients with ocular hypertension when delivered in a gel vehicle. The carbomer gel vehicle, a drug delivery system also used with pilocarpine (Pilopine HS), is used to prolong ocular contact and enhance penetration. The importance of the role of the vehicle in a topical carbonic anhydrase inhibitor has not been assessed.(ABSTRACT TRUNCATED AT 250 WORDS)

The study of ocular hypotensive effect of 6-hydroxyethoxy-2-benzothiazole sulfonamide: a topical carbonic anhydrase inhibitor.

A newly synthesized topical carbonic anhydrase inhibitor, 6-hydroxyethoxy-2-benzothiazole sulfonamide (6-HS), was administered systemically and topically to alpha-chymotrypsin-induced glaucoma rabbits to evaluate its ocular hypotensive effect. A significant IOP lowering effect was observed after topical application of 50 microL of 3% 6-HS gel, but a dose of 50 microL of 3% 6-HS suspension failed to reduce IOP. The maximal magnitude of reduced IOP after topical gel instillation was 24.4%, very close to the result obtained following intravenous injection of 6 mg/kg of 6-HS (23.3%). However, the blood levels of 6-HS after topical instillation with 3% 6-HS gel was much lower than that following 6 mg/kg of 6-HS injected intravenously (less than 5%). Since a lower dose of 6-HS (1 mg/Kg) administered intravenously did not cause a significant drop in IOP, it is reasonable to deduct that the ocular hypotensive effect of 6-HS applied topically can then be attributed to the inhibition of intraocular carbonic anhydrase activity. It was also noted that a larger dose of intravenous administration of 6-HS (20 mg/Kg) had a more profound IOP and blood pressure reducing effect with moderate metabolic acidosis.